Nintedanib – Tyrosine Kinase Inhibitor for Lung Disease

Nintedanib is a potent oral small-molecule tyrosine kinase inhibitor with pronounced antifibrotic and antiangiogenic properties. The drug was developed for the targeted therapy of severe lung diseases and certain types of cancer. Nintedanib blocks key signaling pathways that trigger pathological tissue scarring and vascular proliferation, significantly slowing the progression of destructive changes in the body.

The mechanism of action of nintedanib involves the simultaneous inhibition of growth factor receptors: vascular endothelial growth factor receptors (VEGFR 1–3), fibroblast growth factor receptors (FGFR 1–3), and platelet-derived growth factor receptors (PDGFR α and β). By blocking these receptors, the drug halts the activation, migration, and differentiation of fibroblasts—the primary cells responsible for excessive collagen deposition in lung fibrosis. In cancer treatment, the drug prevents neoangiogenesis (the formation of new vessels), thereby depriving the tumor of nutrients. Nintedanib therapy significantly reduces the annual rate of decline in forced vital capacity (FVC), slowing the loss of respiratory function and improving the patient's long-term prognosis.

The drug is taken orally twice daily and requires constant medical supervision of liver function.

Wikipedia page

Indications

Nintedanib is indicated for adult patients for the treatment of the following serious conditions:

Idiopathic Pulmonary Fibrosis (IPF): long-term therapy to slow disease progression and reduce the rate of decline in lung function.
Systemic Sclerosis (SSc-ILD): treatment of interstitial lung disease associated with systemic sclerosis to reduce lung tissue damage.
Chronic Fibrosing ILDs: therapy for other progressive interstitial lung diseases with a fibrosing phenotype.
Oncology (Lung Cancer): in combination with docetaxel for the treatment of locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.

Dosage and administration

The nintedanib dosing regimen must be strictly followed to achieve therapeutic effects and monitor tolerability.

Standard Dose: the recommended dosage is 150 mg twice daily (every 12 hours).
Administration Method: capsules should be taken orally with food, swallowed whole with a sufficient amount of water. They must not be chewed or crushed.
Dose Adjustment: if side effects occur (e.g., diarrhea or changes in liver function tests), the dose is temporarily reduced to 100 mg twice daily or treatment is interrupted.
Liver Function Monitoring: checking ALT, AST, and bilirubin levels is mandatory before starting treatment and regularly during the first year of therapy.
Missed Dose: if a dose is missed, take the next dose at the usual time. Do not double the dose.

The use of nintedanib is restricted in certain conditions due to the risk of severe complications:

Pregnancy: the drug has teratogenic effects and is strictly contraindicated; reliable contraception is required during and for 3 months after treatment.
Hepatic Impairment: the drug is not recommended for patients with moderate or severe hepatic impairment (Child-Pugh classes B and C).
Hypersensitivity: known allergy to nintedanib, peanuts, soy, or any component of the medication.
Pediatric Use: efficacy and safety in children and adolescents under 18 years of age have not been established.
Bleeding Risk: caution should be exercised in patients with a known risk of bleeding or those taking anticoagulants.

The most common side effects of nintedanib manifest in the digestive system and the liver:

GI Disorders: diarrhea (observed in most patients), nausea, vomiting, and abdominal pain. Timely use of anti-diarrheal agents is crucial.
Hepatotoxicity: elevation of liver enzymes, requiring regular blood monitoring and possible suspension of the course.
Cardiovascular Risks: a small increase in the risk of arterial thromboembolic events and myocardial infarction.
Metabolism: decreased appetite and significant weight loss during long-term therapy.
Coagulation System: possible nosebleeds and a slight increase in the risk of GI perforation.
Skin Reactions: in rare cases, rash or pruritus (itching) may be observed.

Frequently Asked Questions

Nintedanib is a potent tyrosine kinase inhibitor. It works by blocking growth factor receptors (VEGFR, FGFR, and PDGFR) involved in cell signaling pathways that lead to the proliferation of connective tissue. By inhibiting these signals, the drug slows down the formation of scars (fibrosis) in the lungs, helping to preserve lung function and slow the decline in breathing capacity.

Nintedanib is primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. It is also used to treat systemic sclerosis-associated interstitial lung disease (SSc-ILD) and, in combination with other medications, for certain types of lung cancer.

Capsules should be taken twice daily (morning and evening) at approximately equal intervals, strictly with food, and swallowed whole. Diarrhea is a very common side effect. If it occurs, it is important to immediately start taking anti-diarrheal medication (such as loperamide) and stay well-hydrated. If diarrhea becomes severe, a physician may temporarily reduce the dose or interrupt treatment.

Nintedanib can cause elevations in liver enzymes, which may indicate liver cell damage. Consequently, before starting the drug and regularly during the first year of treatment (typically once a month), patients must undergo blood tests for ALT, AST, and bilirubin. If significant abnormalities occur, the physician will adjust the treatment regimen.

Smoking can lower the concentration of nintedanib in the blood plasma, which may potentially reduce the overall benefits of the therapy. Patients are strongly advised to stop smoking entirely before starting the medication to ensure its maximum effectiveness in slowing the progression of lung fibrosis.